Last reviewed 2026-04-20 · How we verify

Levanil (ECTYLUREA)

Phase 2 active Small molecule

Levanil (generic name: ECTYLUREA) is a ectylurea drug. It is currently in Phase 2 development.

Levanil works by interacting with a specific target in the body, although the exact nature of this interaction is not yet understood.

Levanil, also known as Ectylurea, is a small molecule drug of the ectylurea class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Levanil is unclear, with no information available on its patent status, generic manufacturers, or off-patent status. Further research is needed to determine the safety and efficacy of Levanil. As a result, it is not currently available for clinical use.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ECTYLUREA
Drug class	ectylurea
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of Levanil like a key that fits into a lock in the body. When it binds to its target, it can either block or enhance the activity of that target, leading to changes in the body's function. However, without more information, it's difficult to say exactly how Levanil works or what effects it might have on the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Levanil CI brief — competitive landscape report
Levanil updates RSS · CI watch RSS

Frequently asked questions about Levanil

What is Levanil?

Levanil (ECTYLUREA) is a ectylurea drug.

How does Levanil work?

Levanil works by interacting with a specific target in the body, although the exact nature of this interaction is not yet understood.

What is the generic name of Levanil?

ECTYLUREA is the generic (nonproprietary) name of Levanil.

What drug class is Levanil in?

Levanil belongs to the ectylurea class. See all ectylurea drugs at /class/ectylurea.

What development phase is Levanil in?

Levanil is in Phase 2.

Drug class: All ectylurea drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing